GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » EBIT per Share

KLTO (Klotho Neurosciences) EBIT per Share : $-0.20 (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences EBIT per Share?

Klotho Neurosciences's EBIT per Share for the three months ended in Sep. 2024 was $-0.18. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Klotho Neurosciences's EBIT per Share or its related term are showing as below:

KLTO's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.9
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Klotho Neurosciences's EBIT for the three months ended in Sep. 2024 was $-2.91 Mil.


Klotho Neurosciences EBIT per Share Historical Data

The historical data trend for Klotho Neurosciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences EBIT per Share Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22
EBIT per Share
- -

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Mar24 Jun24 Sep24
EBIT per Share Get a 7-Day Free Trial - - - -0.03 -0.18

Klotho Neurosciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Klotho Neurosciences's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBIT per Share(A: Dec. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.574/1044.861
=-0.00

Klotho Neurosciences's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

EBIT per Share(Q: Sep. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-2.914/16.689
=-0.17

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Klotho Neurosciences  (NAS:KLTO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Klotho Neurosciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Klotho Neurosciences Business Description

Traded in Other Exchanges
N/A
Address
13576 Walnut Street, 12th Floor, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.